行情

ATHX

ATHX

Athersys
NASDAQ

实时行情|Nasdaq Last Sale

1.090
+0.080
+7.92%
盘后: 1.070 -0.02 -1.83% 18:39 12/02 EST
开盘
1.010
昨收
1.010
最高
1.110
最低
1.010
成交量
229.35万
成交额
--
52周最高
3.030
52周最低
0.9200
市值
2.56亿
市盈率(TTM)
-2.6501
分时
5日
1月
3月
1年
5年
Athersys Shares Jump After MultiStem Cell Therapy Data Published In Medical Journal
Athersys Inc (NASDAQ: ATHX) announced that a manuscript reporting data from its MUST-ARDS clinical trial 
Benzinga · 2天前
BRIEF-Athersys Publishes Report Of Clinical Trial For Acute Respiratory Distress Syndrome Treatment
reuters.com · 2天前
Athersys gains on publication of cell therapy study results against respiratory disorder
Athersys (NASDAQ:ATHX) has added ~19.6% in the pre-market on above-average volume after the company announced the peer-reviewed publication of results from a placebo-controlled study for its MultiStem cell therapy in patients with
Seekingalpha · 2天前
Report of Placebo-Controlled Clinical Trial Evaluating MultiStem® Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care Medicine
Athersys, Inc. (NASDAQ: ATHX) announced today that a manuscript reporting data from the Company’s MUST-ARDS clinical trial have been published in the peer-reviewed journal Intensive Care Medicine . MUST-ARDS was a randomized, double-blind...
Business Wire · 2天前
Athersys, Inc. (ATHX) Upgraded to Buy: Here's Why
Athersys, Inc. (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks · 11/24 17:00
Why Investors Should Hold on to Universal Health (UHS) Stock
Zacks.com · 11/24 15:17
Is the Options Market Predicting a Spike in Athersys (ATHX) Stock?
Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.
Zacks · 11/22 16:54
SAVA, GTEC and RAAS among mid-day movers
Gainers: Greenland Technologies Corporation (NASDAQ:GTEC) +71%. Longeveron (NASDAQ:LGVN) +37%. Aurora (NASDAQ:AUR) +31%. Bakkt (NYSE:BKKT) +26%. FedNat Holding Company (NASDAQ:FNHC) +18%. UWM Holdings Corporation (NYSE:UWMC) +18%. SCYNEXIS (NASDAQ:SCYX) +1...
Seekingalpha · 11/19 17:38
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ATHX最新的财务预测,通过ATHX每股收益,每股净资产,每股现金流等数据分析Athersys近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
75.00%买入
25.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测ATHX价格均价为4.563,最高价位7.00,最低价为1.250。
最高7.00
均价4.563
最低1.250
现价1.090
EPS
实际EPS
预期EPS
-0.10-0.08-0.05-0.03
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 200
机构持股: 5,770.79万
持股比例: 24.53%
总股本: 2.35亿
类型机构数股数
增持
44
268.92万
建仓
16
44.82万
减持
33
219.76万
平仓
13
49.30万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.49%
制药与医学研究
-0.06%
高管信息
Non-Executive Chairman/Independent Director
Ismail Kola
President/Chief Executive Officer/Chief Operating Officer
William Lehmann
Chief Financial Officer
Ivor Macleod
Executive Vice President/Chief Scientific Officer/Director
John Harrington
Director
Hardy Kagimoto
Director
Kenneth Traub
Independent Director
Katherine Kalin
Independent Director
Lorin Randall
Independent Director
Baiju Shah
Independent Director
Jane Wasman
Independent Director
Jack Wyszomierski
暂无数据
ATHX 简况
Athersys, Inc.是一家国际生物技术公司,专注于再生医学领域。该公司的MultiStem细胞疗法是一种同种异体干细胞产品,是其主要的平台产品,正处于后期临床开发阶段。其临床开发计划的重点是治疗神经系统疾病、心血管疾病、炎症和免疫疾病、某些肺部疾病以及许多患者护理标准有限或不足的其他疾病。

微牛提供Athersys Inc(NASDAQ-ATHX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ATHX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ATHX股票基本功能。